Stryker Corp. (NYSE:SYK) Director Ronda E. Stryker sold 12,000 shares of the stock in a transaction on Wednesday, November 23rd. The stock was sold at an average price of $109.89, for a total value of $1,318,680.00. Following the completion of the transaction, the director now owns 193,142 shares in the company, valued at $21,224,374.38. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Shares of Stryker Corp. (NYSE:SYK) opened at 111.75 on Friday. Stryker Corp. has a 12 month low of $86.68 and a 12 month high of $123.55. The company has a market cap of $41.84 billion, a P/E ratio of 25.43 and a beta of 0.86. The stock’s 50 day moving average price is $113.79 and its 200-day moving average price is $114.99.

Stryker Corp. (NYSE:SYK) last announced its quarterly earnings results on Thursday, October 27th. The medical technology company reported $1.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.37 by $0.02. Stryker Corp. had a return on equity of 23.61% and a net margin of 15.24%. The firm had revenue of $2.83 billion for the quarter, compared to the consensus estimate of $2.81 billion. During the same period in the prior year, the company posted $1.25 earnings per share. The company’s quarterly revenue was up 17.1% on a year-over-year basis. Equities research analysts expect that Stryker Corp. will post $5.78 earnings per share for the current year.

Insider Buying and Selling by Quarter for Stryker Corp. (NYSE:SYK)

Hedge funds and other institutional investors have recently bought and sold shares of the stock. D.A. Davidson & CO. increased its position in Stryker Corp. by 24.4% in the third quarter. D.A. Davidson & CO. now owns 17,715 shares of the medical technology company’s stock worth $2,061,000 after buying an additional 3,480 shares in the last quarter. Piedmont Investment Advisors LLC purchased a new position in Stryker Corp. during the third quarter worth $30,751,000. Colony Group LLC increased its position in Stryker Corp. by 1.9% in the third quarter. Colony Group LLC now owns 3,930 shares of the medical technology company’s stock worth $457,000 after buying an additional 75 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in Stryker Corp. by 6.2% in the third quarter. Price T Rowe Associates Inc. MD now owns 17,503,094 shares of the medical technology company’s stock worth $2,037,535,000 after buying an additional 1,022,233 shares in the last quarter. Finally, LPL Financial LLC increased its position in Stryker Corp. by 1.5% in the third quarter. LPL Financial LLC now owns 35,228 shares of the medical technology company’s stock worth $4,096,000 after buying an additional 509 shares in the last quarter. 73.55% of the stock is currently owned by institutional investors.

Several brokerages have weighed in on SYK. Zacks Investment Research cut Stryker Corp. from a “buy” rating to a “hold” rating in a research note on Tuesday. Needham & Company LLC restated a “hold” rating on shares of Stryker Corp. in a research note on Sunday, November 13th. BMO Capital Markets upgraded Stryker Corp. from an “underperform” rating to a “market perform” rating and set a $125.00 price objective on the stock in a research note on Tuesday, November 1st. They noted that the move was a valuation call. Canaccord Genuity set a $127.00 price objective on Stryker Corp. and gave the company a “buy” rating in a research note on Sunday, October 30th. Finally, Oppenheimer Holdings Inc. set a $122.00 price objective on Stryker Corp. and gave the company a “hold” rating in a research note on Sunday, October 30th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $122.38.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The legal version of this piece can be read at https://www.thecerbatgem.com/2016/11/25/ronda-e-stryker-sells-12000-shares-of-stryker-corp-syk-stock-2.html.

Stryker Corp. Company Profile

Stryker Corporation (Stryker) is a medical technology company. The Company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Company’s Orthopaedics segment products consist of implants used in hip and knee joint replacements and trauma and surgeries. The Company’s MedSurg segment products consist of surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical), and reprocessed and remanufactured medical devices (Sustainability), as well as other medical device products used in a range of medical specialties.

5 Day Chart for NYSE:SYK

Receive News & Stock Ratings for Stryker Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corp. and related stocks with our FREE daily email newsletter.